Business
I got two of the biggest names in Indian pharma into one room, Rajeev Juneja of Mankind and GV Prasad of Dr. Reddy's, who'd somehow never actually met before this, and what came out was part masterclass and part origin story, from why being relentlessly contrarian beat following the herd, to how a college dropout from Meerut turned everything he hated about a medical store into a pharma giant, to why a chemical engineer who says he owes his career to his marriage spent decades chasing one original molecule, and somewhere in between we got into why India makes the world's generics instead of discovering its own drugs, what it really takes in time and money to bring a single drug to market, why GV thinks the AI-will-cure-everything story is overstated, where GLP-1s go next, and the one thing they'd tell a 25-year-old trying to build in pharma.
Timestamps:
00:00 Introduction
04:27 Rajeev Juneja's path from medical-store apprentice to building Mankind
10:11 Mankind's contrarian OTC and bottom-up market strategy
16:23 G.V. Prasad on science and the Dr. Reddy's lineage
23:06 Segmenting the industry and how generic drugs are made
29:15 Why drug purity standards are shared but enforcement differs
36:40 Why India is the pharmacy of the world by volume, not revenue
41:00 How margins are split across the pharma value chain
45:17 Whether online pharmacy and consumer brands are real openings
53:15 Whether hospital roll-up valuations are justified
59:10 Tariffs, Jan Aushadhi and drug price controls
1:03:21 How China built a pharma-innovation ecosystem in a decade
1:10:02 Long-horizon governance and removing entrepreneurial fear
1:15:40 China's incentives, talent and leverage over the US
1:22:01 Why the Ayush and wellness market outgrows pharma
1:25:05 The evidence, quality and standardisation debate around Ayurveda
1:35:13 The sexual-wellness opportunity and the stigma problem
1:40:26 The fertility, IVF and egg-freezing opportunity
1:43:45 The API narrative debate and how a drug is synthesised
1:50:54 Biologics, monoclonal antibodies and vaccines explained
1:55:57 Stem cells and peptides, separating therapy from hype
2:00:06 The semaglutide story and how GLP-1 works
2:05:01 Mankind's ethical-selling philosophy on GLP-1
2:08:06 Why India leads in small molecules but lags in biologics
2:15:07 Where a young founder can enter the GLP-1 wave
2:23:38 The yin and yang of innovators and generics
2:29:05 Diagnostics, CDMO and the China-plus-one opportunity
2:37:18 Applying AI to pharma and the expired-medicine problem
2:43:01 Why founders should never copy a set formula
2:45:30 Succession, home diagnostics and the microfluidics frontier
#nikhilkamath Co-founder of Zerodha and Gruhas
Host of 'WTF is' & 'People By WTF' Podcast
- Twitter: https://x.com/nikhilkamathcio/
- Instagram: https://www.instagram.com/nikhilkamathcio/
- LinkedIn: https://www.linkedin.com/in/nikhilkamathcio utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_app
- Facebook: https://www.facebook.com/nikhilkamathcio/
Rajeev Juneja-Vice Chairman & Managing Director at Mankind Pharma Ltd
G.V Prasad Reddy-MD & Co-Chairman at Dr. Reddy's
Watch 'WTF is' Podcast on Spotify
Watch 'People by WTF' Podcast on Spotify
Watch 'WTF Online' on Spotify
#WTFiswithnikhilkamath #PeopleByWTF #WTFOnline